Status:
COMPLETED
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
Lead Sponsor:
Duke University
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Parexel
Conditions:
Gram-negative Bacteremia
Bloodstream Infection
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized ...
Eligibility Criteria
Inclusion
- Positive blood culture with Gram stain showing GNB
- Hospitalized at the time of Gram stain result
- Enrolled within 16 hours of blood culture positivity
Exclusion
- Positive blood culture for GNB within the prior 7 days (if known at the time of Gram stain result)
- Deceased at the time of Gram stain result
- Gram-positive bacilli, Gram-positive cocci, Gram-negative cocci, yeast, fungi, or multiple morphologies of GNB detected on Gram stain of blood culture
- Previous enrollment in this study
Key Trial Info
Start Date :
December 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 18 2025
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06174649
Start Date
December 22 2023
End Date
June 18 2025
Last Update
July 8 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon University General Hospital
Chaïdári, Attica, Greece, 12462
2
Tzaneio General Hospital
Piraeus, Greece, 18536
3
Kasturba Medical College, Mangalore
Attavāra, Mangalore, India, 575001
4
Rambam Health Care Campus
Haifa, Israel, 3109601